SEC Filing | Amicus Therapeutics

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Prout Samantha

(Last)

(First)

(Middle)

C/O AMICUS THERAPEUTICS, INC.

3675 MARKET STREET

(Street)

PHILADELPHIA

19104

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/10/2023

3. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock⁽¹⁾	137,003	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	⁽²⁾	03/26/2028	Common Stock	2,940	14.88	D
Stock Options (right to buy)	⁽²⁾	01/02/2029	Common Stock	2,376	10.04	D
Stock Options (right to buy)	⁽³⁾	01/02/2030	Common Stock	7,566	9.55	D
Stock Options (right to buy)	⁽⁴⁾	04/15/2030	Common Stock	13,768	10.03	D
Stock Options (right to buy)	⁽⁵⁾	01/04/2031	Common Stock	16,963	21.78	D
Stock Options (right to buy)	⁽⁶⁾	01/14/2032	Common Stock	56,711	12.11	D
Stock Options (right to buy)	⁽⁷⁾	01/03/2033	Common Stock	55,203	11.93	D

Explanation of Responses:

1. The amount shown on this line represents Restricted Stock Units which will vest in varying quantities over the next four years, subject in each case to Ms. Prout's continued service with the Company through the applicable vesting dates.

2. All of the options shown on this line are fully vested and exercisable.

3. These options were granted on January 2, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 5,670 options are vested and exercisable and 1,896 remain unvested.

4. These options were granted on April 15, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,878 options are vested and exercisable and 2,890 remain unvested.

5. These options were granted on January 4, 2021, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,594 options are vested and exercisable and 6,369 remain unvested.

6. These options were granted on January 14, 2022, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 21,263 options are vested and exercisable and 35,448 remain unvested.

7. These options were granted on January 3, 2023, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. All of the options shown on this line are unvested.

Remarks:

	/s/ Christian Formica, Attorney-in-Fact	07/14/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS


     The undersigned hereby constitutes and appoints each of Ellen Rosenberg,
Daphne Quimi and Christian Formica, or any of them signing singly, and with full
power of substitution, the undersigned's true and lawful attorney-in-fact to:

        1.  prepare and execute in the undersigned's name and on the
undersigned's behalf, and submit to the U.S. Securities and Exchange Commission
(the "SEC") a Form ID, including amendments thereto, and any other documents
necessary or appropriate to obtain codes and passwords enabling the undersigned
to make electronic filings with the SEC of reports required by Section16(a) of
the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

        2.  execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Amicus Therapeutics, Inc., a Delaware
corporation (the "Company"), Forms 3, 4, and5 in accordance with Section 16(a)
of the Securities Exchange Act of 1934 and the rules thereunder;

        3.  do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4,
or 5, complete and execute any amendment or amendments thereto, and file any
such Form or amendment with the SEC and any stock exchange or similar authority,
including filing this power of attorney with the SEC; and

        4.  take any other action necessary in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this power of attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act requisite, necessary, or proper to
be done in the exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the request
of the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

     This power of attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 12th day of July, 2023.





                                         /s/ Samantha Prout
                                         Signature

                                         Samantha Prout
                                         Print Name